von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma-Reference-Cited by-同舟云学术

von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma

Published:2008-09 Issue:3 Volume:180 Page:860-866
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Choueiri Toni K.¹,Vaziri Susan A.J.²,Jaeger Erich³,Elson Paul²,Wood Laura²,Bhalla Ish Prasad²,Small Eric J.³,Weinberg Vivian³,Sein Nancy³,Simko Jeff³,Golshayan Ali-Reza²,Sercia Linda²,Zhou Ming²,Waldman Frederic M.³,Rini Brian I.²,Bukowski Ronald M.²,Ganapathi Ram²

Affiliation:

1. Dana-Farber Cancer Institute, Boston, Massachusetts

2. Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

3. University of California, San Francisco Comprehensive Cancer Center, San Francisco, California

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference20 articles.

1. Evolving role of pegylated interferons in metastatic renal cell carcinoma;Choueiri;Expert Rev Anticancer Ther,2003

2. Mutations of the VHL tumour suppressor gene in renal carcinoma;Gnarra;Nat Genet,1994

3. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer;Yang;N Engl J Med,2003